Orchard Therapeutics
OverviewSuggest Edit
Orchard Therapeutics is a biotechnology company, develops and commercializes transformative ex-vivo autologous hematopoietic stem cell gene therapy to restore normal gene function in primary immune deficiencies, metabolic diseases, and hematological disorders. The сompany also develops adenosine deaminase severe combined immunodeficiency, mucopolysaccharidosis type IIIA, and ex-vivo lentiviral gene therapy programs.
| Type | Public | |
| Founded | 2015 | |
| HQ | London, GB | Map |
| Website | orchard-tx.com | |
| Employee Ratings | More |
Recent NewsAll News
- Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
- Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I
- Orchard Therapeutics to Present at Investor Conferences in March
- Orchard Therapeutics Announces Presentation of Clinical Data from Neurometabolic Franchise at 16th Annual WORLD Symposium
Key People/Management at Orchard Therapeutics
Bobby Gaspar
Chief Executive Officer, Director
John Cerio
SVP & Global Head of Human Resources
Anne Dupraz-Poiseau
Chief Regulatory Officer
Adrien Lemoine
Chief Business Officer
Kathryn Payne
SVP, Corporate Communications & External Affairs
John Ilett
Chief of Staff, Chief Legal Officer & Company Secretary
Orchard Therapeutics Office Locations
Orchard Therapeutics has offices in London, Boston, Foster City and Menlo Park
London, GB (HQ)
108 Cannon St
Boston, US
101 Seaport Blvd 7th floor
Boston, US
2 Seaport Ln 8th floor
Foster City, US
1118 Chess Dr
Menlo Park, US
1360 O'Brien Dr
Orchard Therapeutics Financials and Metrics
Orchard Therapeutics Revenue
Orchard Therapeutics's revenue was reported to be £1.66 m in FY, 2018
| GBP | |
|---|---|
Revenue (FY, 2018) | 1.7m |
Gross profit (FY, 2018) | 1.3m |
Gross profit margin (FY, 2018), % | 79.7% |
Net income (FY, 2018) | (184.4m) |
EBIT (FY, 2018) | (188.0m) |
Market capitalization (16-Oct-2020) | 441.0m |
Closing stock price (16-Oct-2020) | 4.5 |
Cash (31-Dec-2018) | 268.7m |
EV | 172.4m |
Orchard Therapeutics's current market capitalization is $441 m.
| GBP | FY, 2018 |
|---|---|
Revenue | 1.7m |
Cost of goods sold | 337.6k |
Gross profit | 1.3m |
Gross profit Margin, % | 80% |
| GBP | FY, 2017 | FY, 2018 |
|---|---|---|
Cash | 71.9m | 268.7m |
Accounts Receivable | 997.6k | 1.7m |
Current Assets | 75.4m | 284.4m |
| GBP | FY, 2017 | FY, 2018 |
|---|---|---|
Cash From Operating Activities | (26.0m) | (78.0m) |
Cash From Investing Activities | (1.2m) | (3.2m) |
Cash From Financing Activities | 92.6m | 283.9m |
Net Change in Cash | 65.3m | 202.6m |
| GBP | FY, 2017 |
|---|---|
Financial Leverage | 1.1 x |
Orchard Therapeutics Cybersecurity Score
Orchard Therapeutics Online and Social Media Presence
770 Twitter followers
Orchard Therapeutics has 770 Twitter Followers. The number of followers has increased 4.8% month over month and increased 10.2% quarter over quarter
Orchard Therapeutics's Trends
Twitter Engagement Stats for @orchard_tx
217
Tweets
429
Following
770
Followers
12
Tweets last 30 days
4.4
Avg. likes per Tweet
100%
Tweets with engagement
Orchard Therapeutics News and Updates
October 16, 2020
Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
First therapy recommended for full marketing authorization in the EU for eligible patients with confirmed diagnosis of late infantile or early juvenile MLD variants
September 28, 2020
Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I
BOSTON and LONDON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to OTL-203, an investigational ex vivo autologous hematopoietic stem …
February 26, 2020
Orchard Therapeutics to Present at Investor Conferences in March
BOSTON and LONDON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global leader in gene therapy, today announced that members of the management team will present at the following investor conferences in March:
February 10, 2020
Orchard Therapeutics Announces Presentation of Clinical Data from Neurometabolic Franchise at 16th Annual WORLD Symposium
BOSTON and LONDON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced upcoming presentations from its neurometabolic franchise at the 16th Annual WORLD Symposium on February 10-13 in Orlando, FL. Accepted abstracts include encore cl…
December 08, 2019
Orchard Therapeutics Showcases Clinical Data at the 61st American Society of Hematology Annual Meeting
BOSTON and LONDON, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, will be presenting new r…
September 30, 2019
Orchard Therapeutics Announces Presentation of New Clinical Data for OTL-200 for Metachromatic Leukodystrophy at Upcoming European Society of Gene & Cell Therapy Annual Congress
Initial Results from Cryopreserved Formulation Clinical Trial Accepted as Poster Presentation Initial Results from Cryopreserved Formulation Clinical Trial Accepted as Poster Presentation
Orchard Therapeutics Blogs
August 06, 2020
Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results
Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results
Content Import
Thu, 08/06/2020 - 07:02
Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results
August 6, 2020 at 7:00 AM EDT
…
August 04, 2020
Orchard Therapeutics to Present at Wedbush PacGrow Healthcare Virtual Conference
BOSTON and LONDON , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020 at 9:10 AM ET . A live webcast of the
July 30, 2020
Orchard Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results
BOSTON and LONDON , July 30, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, August 6, 2020 , at 8:00 a.m. ET to review business updates and its second quarter 2020
July 23, 2020
Next-Generation Gene Therapy Manufacturing: A Key to Long-Term Growth and Sustainability
The post Next-Generation Gene Therapy Manufacturing: A Key to Long-Term Growth and Sustainability appeared first on Orchard Therapeutics.
July 20, 2020
Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I
Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I
Content Import
Mon, 07/20/2020 - 07:01
Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I
…
July 09, 2020
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration
Content Import
Thu, 07/09/2020 - 07:01
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration
July 9, 2020 at 7:00 AM EDT
Thi…
Orchard Therapeutics Frequently Asked Questions
When was Orchard Therapeutics founded?
Orchard Therapeutics was founded in 2015.
Who are Orchard Therapeutics key executives?
Orchard Therapeutics's key executives are Bobby Gaspar, John Cerio and Anne Dupraz-Poiseau.
How many employees does Orchard Therapeutics have?
Orchard Therapeutics has 252 employees.
What is Orchard Therapeutics revenue?
Latest Orchard Therapeutics annual revenue is £1.7 m.
What is Orchard Therapeutics revenue per employee?
Latest Orchard Therapeutics revenue per employee is £6.6 k.
Who are Orchard Therapeutics competitors?
Competitors of Orchard Therapeutics include Aevi Genomic Medicine, AID Genomics and Annexon Biosciences.
Where is Orchard Therapeutics headquarters?
Orchard Therapeutics headquarters is located at 108 Cannon St, London.
Where are Orchard Therapeutics offices?
Orchard Therapeutics has offices in London, Boston, Foster City and Menlo Park.
How many offices does Orchard Therapeutics have?
Orchard Therapeutics has 5 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies